Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

The expression pattern of APC2 and APC7 in various cancer cell lines and AML patients.

Authors: Rahimi, H  Ahmadzadeh, A  Yousef-amoli, S  Kokabee, L  Shokrgozar, MA  Mahdian, R  Karimipoor, M 
Citation: Rahimi H, etal., Adv Med Sci. 2015 Sep;60(2):259-63. doi: 10.1016/j.advms.2015.04.007. Epub 2015 May 13.
Pubmed: (View Article at PubMed) PMID:26046517
DOI: Full-text: DOI:10.1016/j.advms.2015.04.007

PURPOSE: Anaphase promoting complex (APC/C) is an E3 ligase enzyme, which ubiquinates various proteins involved in the cell cycle. This protein complex may have a pivotal role in the cell cycle control affecting pathological conditions such as cancer. APC7 and APC2 subunits of the APC/C complex are involved in the substrate recognition and the catalytic reaction, respectively. MATERIALS AND METHODS: In this study, quantitative Real-time PCR was used to analyse APC2 and APC7 expression in different cancer cell lines as well as AML patient's blood cells. RESULTS: The results showed that APC2 and APC7 subunits were both over expressed in cancer cell lines (p=0.008). The mean expression ratio of APC2 and APC7 in different cancer cells were 2.60+/-0.22 and 4.83+/-0.11, respectively. An increase in expression of APC2 and APC7 was seen among 12 out of 14 AML patients (85%). There was a significant positive correlation between APC2 upregulation and the detection of splenomegaly in the patients (r=0.808, p=0.001). CONCLUSION: This was the first study suggesting that APC/C upregulation may contribute to the pathogenesis of cancer and can be used as a molecular biomarker to predict the progression and the prognosis of AML.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 11067888
Created: 2016-04-27
Species: All species
Last Modified: 2016-04-27
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.